Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CMB305 |
| Trade Name | |
| Synonyms | ID-CMB305|CMB 305 |
| Drug Descriptions |
CMB305 is a combination of LV305, a dendritic cell-targeted lentiviral vector encoding NY-ESO-1, and G305, an NY-ESO-1 cancer vaccine, which may synergize to promote anti-tumor immunity (PMID: 29280411). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C122922 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Aldesleukin + CMB305 + Cyclophosphamide + ID-LV305 | Aldesleukin CMB305 Cyclophosphamide ID-LV305 | 0 | 1 |
| Atezolizumab + CMB305 | Atezolizumab CMB305 | 0 | 0 |
| CMB305 | CMB305 | 0 | 2 |